Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a public biopharmaceutical company based in the Houston, TX area that is developing GP2, a novel peptide immunotherapy, and has commenced a Phase III clinical trial, called Flamingo-01. GP2 is derived from the HER2/neu protein, which is expressed in a variety of common cancers, including breast cancer. Tumors with elevated expression of HER2/neu protein are highly aggressive, resulting in an increased disease recurrence and a worse prognosis. In a Phase IIb clinical trial in the HER2/neu positive adjuvant setting, no breast cancer recurrences were observed after median 5 years of follow-up if the patient was treated, followed, and remained disease free over the first 6 months, which is the time required to reach peak immunity and thus maximum efficacy and protection (p = 0.0338).
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Nationally (across the country)
About Us
Welcome To Greenwich LifeSciences
Greenwich LifeSciences (Nasdaq: GLSI) is a public clinical-stage biopharmaceutical company focused on the development of an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.
Discover
Greenwich LifeSciences’ lead product is GP2, an immunotherapy derived from the HER2/neu protein that is expressed in breast cancer and many other common cancers.
Multiple Studies Have Shown Both Safety and Efficacy
Statistically significant Phase IIb clinical trial data shows that after median 5 years of follow-up, HER2/neu positive breast cancer patients treated with the GP2 immunotherapy had:
- No cancer recurrences if treated, followed, and remained disease-free over the first 6 months
- Peak immunity at 6 months
- No serious adverse events attributable to treatment
- A well tolerated safety profile
- Greenwich LifeSciences has commenced a Phase III clinical trial, Flamingo-01, that is conservatively designed to reproduce the Phase IIb clinical trial results and to continue to save lives.
For the 146 patients who have been treated with GP2 immunotherapy to date over 4 clinical trials, treatment was well tolerated and no serious adverse events were observed related to the immunotherapy.
Breast Cancer Statistics
Statistic #1
One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 282,000 new breast cancer patients and 3.8 million breast cancer survivors in 2021, all of whom have the potential to experience breast cancer recurrences.
Statistic #2
HER2/neu positive breast cancer patients comprise approximately 25% of all breast cancer patients.